Recommendations Recommendations
People have the right to be involved in discussions and make informed decisions about their care, as described in your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
1.1 Team working in the management of heart failure
The core specialist heart failure multidisciplinary team (MDT) should work in collaboration with the primary care team, and should include: a lead physician with subspecialty training in heart failure (usually a consultant cardiologist) who is responsible for making the clinical diagnosis a specialist heart failure nurse a healthcare professional with expertise in specialist prescribing for heart failure.
[2018] [2018] 1.1.2
The specialist heart failure MDT should: diagnose heart failure give information to people newly diagnosed with heart failure (see giving information to people with heart failure) manage newly diagnosed, recently decompensated or advanced heart failure (NYHA [New York Heart Association] class III to IV) optimise treatment start new medicines that need specialist supervision continue to manage heart failure after an interventional procedure such as implantation of a cardioverter defibrillator or cardiac resynchronisation device manage heart failure that is not responding to treatment. [2018] [2018] Chronic heart failure in adults: diagnosis and management (NG106) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).
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The specialist heart failure MDT should directly involve, or refer people to, other services, including rehabilitation, services for older people and palliative care services, as needed. [2018] [2018] 1. 1.4 The primary care team should carry out the following for people with heart failure at all times, including periods when the person is also receiving specialist heart failure care from the MDT: ensure effective communication links between different care settings and clinical services involved in the person's care lead a full review of the person's heart failure care, which may form part of a long-term conditions review recall the person at least every 6 months and update the clinical record ensure that changes to the clinical record are understood and agreed by the person with heart failure and shared with the specialist heart failure MDT arrange access to specialist heart failure services if needed. [2018] [2018] Care after an acute e Care after an acute ev vent ent For recommendations on the diagnosis and management of acute heart failure see NICE's guideline on acute heart failure.
1.1.5
People with heart failure should generally be discharged from hospital only when their clinical condition is stable and the management plan is optimised.
Timing of discharge should take into account the wishes of the person and their family or carer, and the level of care and support that can be provided in the community. [2003] [2003] 1.1.6
The primary care team should take over routine management of heart failure as soon as it has been stabilised and its management optimised. [2018] [2018] Writing a care plan Writing a care plan 1.1.7
The specialist heart failure MDT should write a summary for each person with heart failure that includes:
Chronic heart failure in adults: diagnosis and management (NG106) diagnosis and aetiology medicines prescribed, monitoring of medicines, when medicines should be reviewed and any support the person needs to take the medicines functional abilities and any social care needs social circumstances, including carers' needs. [2018] [2018] 1.1.8
The summary should form the basis of a care plan for each person, which should include:
plans for managing the person's heart failure, including follow-up care, rehabilitation and access to social care symptoms to look out for in case of deterioration a process for any subsequent access to the specialist heart failure MDT if needed contact details for a named healthcare coordinator (usually a specialist heart failure nurse) alternative local heart failure specialist care providers, for urgent care or review.
additional sources of information for people with heart failure. [2018] [2018] 1.1.9
Give a copy of the care plan to the person with heart failure, their family or carer if appropriate, and all health and social care professionals involved in their care.
[2018] [2018] Review alternative causes for symptoms of heart failure in people with NT-proBNP levels below 400 ng/litre. If there is still concern that the symptoms might be related to heart failure, discuss with a physician with subspeciality training in heart failure. [ More detailed monitoring will be needed if the person has significant comorbidity or if their condition has deteriorated since the previous review. 
Terms used in this guideline
Heart failure with preserv Heart failure with preserved ejection fr ed ejection fraction action This is usually associated with impaired left ventricular relaxation, rather than left ventricular contraction, and is characterised by normal or preserved left ventricular ejection fraction with evidence of diastolic dysfunction .
Heart failure with reduced ejection fr Heart failure with reduced ejection fraction action Heart failure with an ejection fraction below 40%.
Miner Mineralocorticoid receptor antagonist alocorticoid receptor antagonist
A drug that antagonises the action of aldosterone at mineralocorticoid receptors.
[1] See team working in the management of heart failure in this guideline.
[2] This is a minimum. People with comorbidities or co-prescribed medications will need further monitoring. Monitoring serum potassium is particularly important if a person is taking digoxin or an
MRA.
Chronic heart failure in adults: diagnosis and management (NG106) NICE has produced tools and resources to help you put this guideline into practice.
Putting recommendations into practice can take time. How long may vary from guideline to guideline, and depends on how much change in practice or services is needed. Implementing change is most effective when aligned with local priorities.
Changes recommended for clinical practice that can be done quickly -like changes in prescribing practice -should be shared quickly. This is because healthcare professionals should use guidelines to guide their work -as is required by professional regulating bodies such as the General Medical and Nursing and Midwifery Councils.
Changes should be implemented as soon as possible, unless there is a good reason for not doing so (for example, if it would be better value for money if a package of recommendations were all implemented at once).
Different organisations may need different approaches to implementation, depending on their size and function. Sometimes individual practitioners may be able to respond to recommendations to improve their practice more quickly than large organisations.
Here are some pointers to help organisations put NICE guidelines into practice:
1. Raise a Raise awareness wareness through routine communication channels, such as email or newsletters, regular meetings, internal staff briefings and other communications with all relevant partner organisations. Identify things staff can include in their own practice straight away.
Identify a lead
Identify a lead with an interest in the topic to champion the guideline and motivate others to support its use and make service changes, and to find out any significant issues locally.
Carry out a baseline assessment
Carry out a baseline assessment against the recommendations to find out whether there are gaps in current service provision.
Think about what data y
Think about what data you need to measure impro ou need to measure improv vement ement and plan how you will collect it. You may want to work with other health and social care organisations and specialist groups to compare current practice with the recommendations. This may also help identify local issues that will slow or prevent implementation.
Chronic heart failure in adults: diagnosis and management (NG106) 5. De Dev velop an action plan elop an action plan, with the steps needed to put the guideline into practice, and make sure it is ready as soon as possible. Big, complex changes may take longer to implement, but some may be quick and easy to do. An action plan will help in both cases.
6. F For v or very big changes ery big changes include milestones and a business case, which will set out additional costs, savings and possible areas for disinvestment. A small project group could develop the action plan.
The group might include the guideline champion, a senior organisational sponsor, staff involved in the associated services, finance and information professionals.
7. Implement the action plan Implement the action plan with oversight from the lead and the project group. Big projects may also need project management support.
8. Re Review and monitor view and monitor how well the guideline is being implemented through the project group.
Share progress with those involved in making improvements, as well as relevant boards and local partners.
NICE provides a comprehensive programme of support and resources to maximise uptake and use of evidence and guidance. See our into practice pages for more information.
Also see Leng G, Moore V, Abraham S, editors (2014) Achieving high quality care -practical experience from NICE. Chichester: Wiley.
Chronic heart failure in adults: diagnosis and management (NG106)
Interdisciplinary working has contributed to better outcomes in heart failure but there is further room to improve the provision of multidisciplinary teams (MDTs) and integrate them more fully into healthcare processes. This update highlights and further expands on the roles of the MDT and collaboration between the MDT and the primary care team.
The 2013 cardiovascular disease outcomes strategy also noted that the proportion of people with heart failure who have cardiac rehabilitation was around 4%, and that increasing this proportion would reduce mortality and hospitalisation. This update recommends that all people with heart failure are offered an easily accessible, exercise-based cardiac rehabilitation programme, if this is suitable for them.
More information
To find out what NICE has said on topics related to this guideline, see our web page on cardiovascular conditions.
Recommendations for research Recommendations for research
The guideline committee has made the following recommendations for research. The committee's full set of research recommendations is detailed in the full guideline. 
Cardiac MRI versus other imaging techniques for diagnosing heart failure
What is the optimal imaging technique for the diagnosis of heart failure?
Wh Why this is important y this is important
The 3 The impact of atrial fibrillation on the natriuretic peptide threshold for diagnosing heart failure
What is the optimal NT-proBNP threshold for the diagnosis of heart failure in people with atrial fibrillation?
Wh Why this is important y this is important Atrial fibrillation is a common arrhythmia in the general population, and occurs in 30 to 40% of people with heart failure. Atrial fibrillation can raise the level of serum natriuretic peptides, including NT-proBNP, even in the absence of heart failure. This is complicated further in heart failure with preserved ejection fraction, in which 2 echocardiographic diagnostic criteria become unreliable (the left atrial volume and the tissue doppler imaging assessment of diastolic function).
These factors contribute to the complexity of the diagnosis and have a potential impact on the usual thresholds for NT-proBNP in people who have atrial fibrillation. This has been recognised in several ongoing randomised controlled trials of heart failure, which are using higher NT-proBNP thresholds for the diagnosis of heart failure in people with atrial fibrillation.
The impact of advanced kidney disease on the natriuretic peptide threshold for diagnosing heart failure
What are the optimal NT-proBNP thresholds for diagnosing heart failure in people with stage IIIb, IV or V chronic kidney disease?
Wh Why this is important y this is important
Heart failure incidence and prevalence increase with age, with the rise starting at age 65 and peaking between 75 and 85. Both advancing age and heart failure are associated with a gradual and progressive decline in renal function. In addition, the progression of heart failure and some treatments for heart failure lead to progressive deterioration of renal function. A decline in renal function is associated with increased fluid retention and a rise in the level of the serum natriuretic peptides, including NT-proBNP, even in the absence of heart failure. There is some evidence that the use of higher NT-proBNP thresholds would improve diagnostic accuracy for heart failure in people with significant deterioration of creatinine clearance.
Risk tools for predicting non-sudden death in heart failure
What is the most accurate prognostic risk tool in predicting 1-year mortality from heart failure at specific clinically relevant thresholds (for example, sensitivity, specificity, negative predictive value and positive predictive value at a threshold of 50% risk of mortality at 1 year)?
Wh Why this is important y this is important
There are a number of validated prognostic risk tools for heart failure but most do not report sensitivity and specificity at clinically relevant thresholds. This information is crucial to enable accurate prediction of a person's risk of mortality. The ability to accurately predict a person's prognosis would allow clearer communication and timely referral to other services such as palliative care. Inaccurate prediction has the potential to lead to significant psychological harm and increased morbidity. Chronic heart failure in adults: diagnosis and management (NG106) Accreditation Chronic heart failure in adults: diagnosis and management (NG106)
